Filing Details
- Accession Number:
- 0000874716-24-000131
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-09-09 16:18:53
- Reporting Period:
- 2024-09-05
- Accepted Time:
- 2024-09-09 16:18:53
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
874716 | Idexx Laboratories Inc | IDXX | In Vitro & In Vivo Diagnostic Substances (2835) | 010393723 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1094176 | Anne M Szostak | One Idexx Drive Westbrook ME 04092 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2024-09-05 | 500 | $0.00 | 6,061 | No | 4 | G | Indirect | Trust of M. Anne Szostak |
Common Stock | Acquisiton | 2024-09-05 | 500 | $0.00 | 500 | No | 4 | G | Indirect | The O'Hanian-Szostak Family Foundation |
Common Stock | Disposition | 2024-09-06 | 500 | $469.37 | 0 | No | 4 | S | Indirect | The O'Hanian-Szostak Family Foundation |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | G | Indirect | Trust of M. Anne Szostak |
No | 4 | G | Indirect | The O'Hanian-Szostak Family Foundation |
No | 4 | S | Indirect | The O'Hanian-Szostak Family Foundation |
Footnotes
- The reporting person is the settlor of the Trust of M. Anne Szostak ("Trust") and the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares held by the Trust.
- The reporting person is a trustee of The O'Hanian-Szostak Family Foundation ('Foundation') and has power to direct the distribution of assets held by the Foundation.
- Represents the weighted average price of the shares sold ranging from a low of $468.98 to a high of $469.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.